Susan Nichols

Susan Nichols is the CEO of Propel Biosciences and a recognized C-suite leader in cell and gene therapy, bringing deep experience as a CEO, CBO, and CCO-level operator specializing in growth-stage commercialization and organizational build-out. With more than two decades across drug development, CDMO services, and advanced therapy manufacturing, she has led high-performing teams in both emerging biotech ventures and global organizations including Invetech/Danaher, Thermo Fisher/ASI, Hitachi Chemical, and Roche Diagnostics. At Propel Biosciences, Susan leads a commercialization acceleration firm that helps biotech and advanced therapy organizations translate complex science into clear market positioning, early revenue traction, and scalable commercial infrastructure. She works hands-on with leadership teams to define differentiated narratives, build disciplined go-to-market models, and operationalize growth with speed and precision. Propel provides outsourced business development and sa